MEDICURE INC (MPH.CA) Stock Overview
Canada - TSX-V:MPH - CA58469E4085 - Common Stock
MPH.CA Key Statistics, Chart & Performance
The current stock price of MPH.CA is 1.09 CAD. In the past month the price decreased by -5.22%. In the past year, price increased by 5.83%.
MPH.CA Latest News, Press Relases and Analysis
MPH.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 443.43M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 387.09M | ||
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 352.61M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 159.63M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 131.79M | ||
| NRX.CA | NUREXONE BIOLOGIC INC | N/A | 60.23M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 27.25 | 59.78M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 36.02M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.18M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 27.24M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 18.40M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 11.41M |
Related stock screener links
About MPH.CA
Company Profile
Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
Company Info
MEDICURE INC
1250 Waverley Street
Winnipeg MANITOBA R3T 6C6 CA
CEO: Albert D. Friesen
Employees: 38
Phone: 12044877412
MEDICURE INC / MPH.CA FAQ
Can you describe the business of MEDICURE INC?
Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
Can you provide the latest stock price for MEDICURE INC?
The current stock price of MPH.CA is 1.09 CAD. The price decreased by -0.91% in the last trading session.
Does MPH stock pay dividends?
MPH.CA does not pay a dividend.
How is the ChartMill rating for MEDICURE INC?
MPH.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists MPH stock?
MPH.CA stock is listed on the TSX Venture Exchange exchange.
Can you provide the PE ratio for MPH stock?
MEDICURE INC (MPH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
Should I buy MPH stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MPH.CA.
MPH.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MPH.CA. When comparing the yearly performance of all stocks, MPH.CA is a bad performer in the overall market: 83.36% of all stocks are doing better.
MPH.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MPH.CA. The financial health of MPH.CA is average, but there are quite some concerns on its profitability.
MPH.CA Financial Highlights
Over the last trailing twelve months MPH.CA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 48.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.76% | ||
| ROE | -7.39% | ||
| Debt/Equity | 0.03 |